---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014129"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:11:25.408717+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics FY2025 revenue drops 85% to $0.6M; net loss $46.9M; cash burn accelerates

## Summary
- Revenue fell to $0.6M from $3.9M in 2024; net loss was $46.9M ($35.25/share) vs $37.6M.
- Cash at $11.9M, down from $29.7M; adjusted EBITDA loss improved to $28.0M from $33.5M.
- Received CDSCO license for PCR Pro instrument in India; expanding to South Asia with $13B addressable market.
- Planning initial FDA 510(k) for flu A/B/RSV test, dropping COVID from initial submission to accelerate timeline.
- Closed stock offerings raising $10.8M; engaged Maxim Group for potential SPAC for CoSara.

## SEC filing metadata
- accession: 0001493152-26-014129
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/0001493152-26-014129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014129
- JSON: https://secwatch.observer/filing/0001493152-26-014129.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014129.txt

## Key facts
- Earnings Releases
  Co-Diagnostics, Inc. reported full year ended December 31, 2025 results: revenue $0.6 million, net income net loss of $46.9 million, EPS $35.25 per share.
  - Period: full year ended December 31, 2025
  - Revenue: $0.6 million
  - Net income: net loss of $46.9 million
  - EPS: $35.25 per share
  - Result: reported results
  source text: the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results: ● Revenue of $0.6 million, compared to $3.9 million in 2024, primarily due to lower grant revenue ● Operating expenses of $50.6 million, compared to $43.0 million in 2024, driven by a non-cash impairment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1692415/000149315226014129/0001493152-26-014129-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.